Sanofi prostate cancer drug shows 28 percent survival
May 27th, 2010 Posted in prostate cancerThe outcome of a final-stage trial showed that Sanofi-Aventis’ cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment
The clinical trial results will be presented at the 2010 American Society of Clinical Oncology (ASCO) on June 6.